A mass balance study of [(14)C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans

SHR6390 (dalpiciclib) is a selective and effective cyclin-dependent kinase (CDK) 4/6 inhibitor and an effective cancer therapeutic agent. On 31 December 2021, the new drug application was approved by National Medical Product Administration (NMPA). The metabolism, mass balance, and pharmacokinetics o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hua, Yan, Shu, Zhan, Yan, Ma, Sheng, Bian, Yicong, Li, Shaorong, Tian, Junjun, Li, Guangze, Zhong, Dafang, Diao, Xingxing, Miao, Liyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102643/
https://www.ncbi.nlm.nih.gov/pubmed/37063263
http://dx.doi.org/10.3389/fphar.2023.1116073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102643/
https://www.ncbi.nlm.nih.gov/pubmed/37063263
http://dx.doi.org/10.3389/fphar.2023.1116073

Ejemplares similares